11,631 results match your criteria: "Spinal Muscular Atrophy"

Lumbar Transforaminal Injections of Nusinersen in Spinal Muscular Atrophy Patients.

Neuroimaging Clin N Am

February 2025

Department of Radiology, Section of Vascular and Interventional Radiology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA. Electronic address:

Following a review of spinal muscular atrophy pathogenesis and current therapeutics, a comprehensive review of transforaminal lumbar injections is provided. Patient preparation, special considerations, procedural technique, complications, and alternative approaches are discussed.

View Article and Find Full Text PDF

Copy Number Association with Spinal Muscular Atrophy Severity: Insights from Colombian Patients.

J Clin Med

October 2024

Facultad de Ciencias de la Salud, Centro de Investigaciones en Ciencias de la Vida, Universidad Simón Bolívar, Barranquilla, Atlántico 080003, Colombia.

Article Synopsis
View Article and Find Full Text PDF

: This systematic review evaluated the impact of nusinersen therapy on respiratory health and function in individuals with spinal muscular atrophy (SMA) and determined whether nusinersen improves pulmonary function, focusing on differences based on patient age and the timing of treatment initiation. : A systematic search of PubMed, Ovid Medline, ScienceDirect, and Web of Science databases was conducted up to January 2024 in accordance with the PRISMA guidelines. Thirteen studies were included, comprising clinical trials, observational studies, and case series that focused on respiratory outcomes in SMA patients treated with nusinersen.

View Article and Find Full Text PDF

Liver SMN restoration rescues the Smn mouse model of spinal muscular atrophy.

EBioMedicine

December 2024

Regenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada; Department of Medicine, University of Ottawa, Ottawa, Canada. Electronic address:

Background: The liver is a key metabolic organ, acting as a hub to metabolically connect various tissues. Spinal muscular atrophy (SMA) is a neuromuscular disorder whereby patients have an increased susceptibility to developing dyslipidaemia and liver steatosis. It remains unknown whether fatty liver is due to an intrinsic or extrinsic impact of survival motor neuron (SMN) protein depletion.

View Article and Find Full Text PDF

We consider the challenges associated with causal inference in settings where data from a randomized trial are augmented with control data from an external source to improve efficiency in estimating the average treatment effect (ATE). This question is motivated by the SUNFISH trial, which investigated the effect of risdiplam on motor function in patients with spinal muscular atrophy. While the original analysis used only data generated by the trial, we explore an alternative analysis incorporating external controls from the placebo arm of a historical trial.

View Article and Find Full Text PDF

Purpose: Some patients with spinal muscular atrophy and scoliosis require CT guidance during injections of nusinersen. The radiation applied to the operator in such procedures becomes an important issue in terms of staff health and safety. The aim of the study was to assess the operator's radiation exposure during CT-guided nusinersen injections in patients with spinal muscular atrophy and scoliosis.

View Article and Find Full Text PDF

Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs.

Cell Mol Neurobiol

November 2024

CureScience, 5820 Oberlin Dr, Suite 202, San Diego, CA, 92121, USA.

Spinal muscular atrophy (SMA) is an autosomal recessive genetic neuromuscular disorder that is characterized by gradual muscle weakness and atrophy due to the degeneration of alpha motor neurons that are present on the anterior horn of the spinal cord. Despite the comprehensive investigations conducted by global scientists, effective treatments or interventions remain elusive. The time- and resource-intensive nature of the initial stages of drug research underscores the need for alternate strategies like drug repurposing.

View Article and Find Full Text PDF

Purpose Of Review: The aim of the review was to provide an overview of safety and efficacy of the available treatments including information from both clinical trials and real-world data. Additional information form ongoing studies using other approaches than increasing SMN protein are also reported.

Recent Findings: In the last 3 years, there have been over 24 studies reporting safety and the impact of the available drugs on different aspects of function, including respiratory and bulbar function.

View Article and Find Full Text PDF

Background: The copy number status (CNS) of the survival motor neuron (SMN) gene may influence the risk and prognosis of amyotrophic lateral sclerosis (ALS) and lower motor neuron diseases (LMND) other than spinal muscular atrophy (SMA). However, previous studies of this association, mainly from Europe, have yielded controversial results, suggesting possible regional differences. Here, we investigated the effect of the SMN gene in Japanese patients with ALS and LMND.

View Article and Find Full Text PDF

Spinal muscular atrophy (SMA) is characterized by low levels of the ubiquitously expressed Survival Motor Neuron (SMN) protein, leading to progressive muscle weakness and atrophy. Skeletal muscle satellite cells play a crucial role in muscle fiber maintenance, repair, and remodelling. While the effects of SMN depletion in muscle are well documented, its precise role in satellite cell function remains largely unclear.

View Article and Find Full Text PDF

Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies.

Arq Neuropsiquiatr

November 2024

Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro RJ, Brazil.

Article Synopsis
  • Spinal muscular atrophy (SMA-5q) is a serious neurodegenerative condition that leads to muscle weakness and atrophy, with SMA 1 showing symptoms in infancy; early treatment improves outcomes.
  • This study assessed the safety and effectiveness of two treatments—nusinersen and onasemnogene abeparvovec (OA)—in children with SMA 1 by evaluating their motor, respiratory, and feeding functions.
  • Results showed that patients who started treatment earlier saw significantly better improvements, with 70% achieving motor milestones, no serious side effects, and most maintaining respiratory and feeding functions.
View Article and Find Full Text PDF

Gene therapy for spinal muscular atrophy: timing is key.

Lancet Reg Health Eur

December 2024

MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford and NIHR Oxford Biomedical Research Center, Oxford OX3 9DU, United Kingdom.

View Article and Find Full Text PDF
Article Synopsis
  • * In a study involving over 103,000 newborns in Zhejiang Province, multiplex real-time PCR detected genetic markers associated with these disorders, leading to 122 samples requiring further testing.
  • * The study identified several cases of SCID, XLA, and SMA, with positive predictive values indicating effectiveness of the screening method, suggesting potential for broader implementation of NBS across China.
View Article and Find Full Text PDF
Article Synopsis
  • - Autosomal recessive spinal muscular atrophy (SMA) often leads to severe infant mortality, primarily linked to deletions in the SMN1 gene, particularly exon 7, but routine tests may miss other crucial genetic variants.
  • - Two Chinese SMA patients showed developmental delays and reduced muscle strength; standard tests revealed atypical results, with only one SMN1 copy identified, suggesting misdiagnosis.
  • - By employing RNA sequencing and ultra-long read sequencing, researchers discovered a rare deletion of exons 2a-5 in both patients, highlighting the need for advanced genetic testing in confirming SMA diagnoses.
View Article and Find Full Text PDF

Introduction: The neck-shaft angle and head-shaft angle in children with varying levels of neurological disability were evaluated to define change over different ages.

Methods: Children aged 1-12 years with spastic cerebral palsy, spinal muscular atrophy types 1 and 2, or typical development were reviewed to evaluate the neck-shaft angle and head-shaft angle. Patients were divided into five groups: Gross Motor Function Classification System levels I and II, Gross Motor Function Classification System level III, Gross Motor Function Classification System levels IV and V, spinal muscular atrophy types 1 and 2, and typical development.

View Article and Find Full Text PDF

Introduction: Molecular chaperones and co-chaperones are highly conserved cellular components that perform a variety of duties related to the proper three-dimensional folding of the proteome. The web of factors that carries out this essential task is called the proteostasis network (PN). Ribonucleoproteins (RNPs) represent an underexplored area in terms of the connections they make with the PN.

View Article and Find Full Text PDF

New evidence of vascular defects in neurodegenerative diseases revealed by single cell RNA sequencing.

Clin Sci (Lond)

November 2024

Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, China.

Neurodegenerative diseases (NDs) involve the progressive loss of neuronal structure or function in the brain and spinal cord. Despite their diverse etiologies, NDs manifest similar pathologies. Emerging research identifies vascular defects as a previously neglected hallmark of NDs.

View Article and Find Full Text PDF